IPRIVASK
LOE ApproachingBLASUBCUTANEOUSINJECTABLE
Approved
Apr 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IPRIVASK is a subcutaneous injectable biologic approved by BLA in April 2003, currently approaching loss of exclusivity. The specific indication and mechanism of action are not disclosed in available data, limiting characterization of its therapeutic role.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating a consolidation-phase team likely focused on defending market share rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IPRIVASK currently shows no linked job openings, reflecting its late-lifecycle stage and mature market position under Bausch + Lomb ownership. Career opportunities on this product are likely limited to maintenance roles rather than growth-oriented positions.
Brand ManagerField Sales Representative
Worked on IPRIVASK at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.